{"id":23672,"date":"2021-10-04T17:00:00","date_gmt":"2021-10-04T11:30:00","guid":{"rendered":"https:\/\/cardiophile.org\/?p=23672"},"modified":"2021-10-05T17:18:46","modified_gmt":"2021-10-05T11:48:46","slug":"cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/","title":{"rendered":"Most important cardiotoxicity of immune checkpoint inhibitors &#8211; Cardiology MCQ &#8211; Answer"},"content":{"rendered":"<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/ZTVUQrfCdOc\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/p>\n<h1><span style=\"color: #008000;\">Most important cardiotoxicity of immune checkpoint inhibitors &#8211; Answer<\/span><\/h1>\n<p><strong><span style=\"color: #0000ff;\">Cardiotoxicity of immune checkpoint inhibitors &#8211; Correct answer: 1. Fulminant myocarditis<\/span><\/strong><br>Immunotherapy with immune checkpoint inhibitors is becoming standard of care for multiple types of malignancies.&nbsp;Important immune checkpoint inhibitors are&nbsp;ipilimumab which acts against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4); nivolumab and pembrolizumab which act against&nbsp;programmed cell death 1 (PD-1) and&nbsp;atezolizumab which targets PD-1 ligand (PD-L1).<\/p>\n<p>Autoimmune fulminant myocarditis has been described in persons treated with immune checkpoint inhibitors [2]. It is associated with profound hemodynamic compromise progressing to circulatory collapse. Mechanism of toxicity is possibly related to the role of PD-1 in protecting the cardiomyocyte from autoimmune attacks [3].<\/p>\n<p><strong><span style=\"color: #0000ff;\">References<\/span><\/strong><\/p>\n<ol>\n<li>Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, Marone G, Tocchetti CG.&nbsp;Cardiotoxicity of immune checkpoint inhibitors.&nbsp;ESMO Open. 2017 Oct 26;2(4):e000247.<\/li>\n<li>Frigeri M, Meyer P, Banfi C, Giraud R, Hachulla AL, Spoerl D, Friedlaender A, Pugliesi-Rinaldi A, Dietrich PY. Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists.&nbsp;Can J Cardiol. 2018 Jan;34(1):92.e1-92.e3.<\/li>\n<li>Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22491251\">PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis<\/a>.&nbsp;J Immunol. 2012 May 15;188(10):4876-84.<\/li>\n<\/ol>\n<p><a href=\"https:\/\/cardiophile.org\/most-important-cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq\/\">Back to question<\/a><\/p>\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Most important cardiotoxicity of immune checkpoint inhibitors &#8211; Answer: 1.  Fulminant myocarditis. Important immune checkpoint inhibitors are\u00a0ipilimumab, nivolumab, pembrolizumab and\u00a0atezolizumab.<\/p>\n","protected":false},"author":1,"featured_media":51618,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[3,5],"tags":[],"class_list":["post-23672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cardiology-mcq","category-dm-dnb-cardiology-entrance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>cardiotoxicity of immune checkpoint inhibitors - Answer<\/title>\n<meta name=\"description\" content=\"Most important cardiotoxicity of immune checkpoint inhibitors - Ipilimumab, nivolumab, pembrolizumab and\u00a0atezolizumab - Answer: 1. Fulminant myocarditis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"cardiotoxicity of immune checkpoint inhibitors - Answer\" \/>\n<meta property=\"og:description\" content=\"Most important cardiotoxicity of immune checkpoint inhibitors - Ipilimumab, nivolumab, pembrolizumab and\u00a0atezolizumab - Answer: 1. Fulminant myocarditis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-04T11:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-05T11:48:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/10\/Cardiology-MCQ.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"676\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Most important cardiotoxicity of immune checkpoint inhibitors &#8211; Cardiology MCQ &#8211; Answer\",\"datePublished\":\"2021-10-04T11:30:00+00:00\",\"dateModified\":\"2021-10-05T11:48:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/\"},\"wordCount\":215,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Cardiology-MCQ.gif\",\"articleSection\":[\"Cardiology MCQ\",\"DM \\\/ DNB Cardiology Entrance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/\",\"name\":\"cardiotoxicity of immune checkpoint inhibitors - Answer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Cardiology-MCQ.gif\",\"datePublished\":\"2021-10-04T11:30:00+00:00\",\"dateModified\":\"2021-10-05T11:48:46+00:00\",\"description\":\"Most important cardiotoxicity of immune checkpoint inhibitors - Ipilimumab, nivolumab, pembrolizumab and\u00a0atezolizumab - Answer: 1. Fulminant myocarditis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Cardiology-MCQ.gif\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Cardiology-MCQ.gif\",\"width\":1200,\"height\":676},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Most important cardiotoxicity of immune checkpoint inhibitors &#8211; Cardiology MCQ &#8211; Answer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"cardiotoxicity of immune checkpoint inhibitors - Answer","description":"Most important cardiotoxicity of immune checkpoint inhibitors - Ipilimumab, nivolumab, pembrolizumab and\u00a0atezolizumab - Answer: 1. Fulminant myocarditis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/","og_locale":"en_US","og_type":"article","og_title":"cardiotoxicity of immune checkpoint inhibitors - Answer","og_description":"Most important cardiotoxicity of immune checkpoint inhibitors - Ipilimumab, nivolumab, pembrolizumab and\u00a0atezolizumab - Answer: 1. Fulminant myocarditis.","og_url":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2021-10-04T11:30:00+00:00","article_modified_time":"2021-10-05T11:48:46+00:00","og_image":[{"width":1200,"height":676,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/10\/Cardiology-MCQ.gif","type":"image\/gif"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Most important cardiotoxicity of immune checkpoint inhibitors &#8211; Cardiology MCQ &#8211; Answer","datePublished":"2021-10-04T11:30:00+00:00","dateModified":"2021-10-05T11:48:46+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/"},"wordCount":215,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/10\/Cardiology-MCQ.gif","articleSection":["Cardiology MCQ","DM \/ DNB Cardiology Entrance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/","url":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/","name":"cardiotoxicity of immune checkpoint inhibitors - Answer","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/10\/Cardiology-MCQ.gif","datePublished":"2021-10-04T11:30:00+00:00","dateModified":"2021-10-05T11:48:46+00:00","description":"Most important cardiotoxicity of immune checkpoint inhibitors - Ipilimumab, nivolumab, pembrolizumab and\u00a0atezolizumab - Answer: 1. Fulminant myocarditis.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/10\/Cardiology-MCQ.gif","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2021\/10\/Cardiology-MCQ.gif","width":1200,"height":676},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/cardiotoxicity-of-immune-checkpoint-inhibitors-cardiology-mcq-answer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Most important cardiotoxicity of immune checkpoint inhibitors &#8211; Cardiology MCQ &#8211; Answer"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/23672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=23672"}],"version-history":[{"count":3,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/23672\/revisions"}],"predecessor-version":[{"id":51617,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/23672\/revisions\/51617"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/51618"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=23672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=23672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=23672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}